At Astellas, our full energy is devoted to further pursuing the interests of patients delivering new drugs that fulfill unmet medical needs around the world.

---

• Financial Targets FY2014
• Payout policy

• Basic Policy and Strategy
• Growth strategy

• Efficiency strategy

Financial Targets and Payout policy

Financial Targets FY2014

Payout policy

Leveraging Our Strengths to Grow

Basic Policy and Strategy

At Astellas, we will overcome decreases in sales and earnings from the expiration of U.S. patents for immunosuppressant Prograf and Harnal, a treatment for functional symptoms of benign prostatic hyperplasia, and accelerate growth to a new stage by leveraging our strengths.

Growth strategy

Urology	Astellas will aim to become No. 1 in the global overactive bladder market through the growth of Vesicare and mirabegron, an upcoming new product, and establish a dominant presence in the urology field.
Transplants	Astellas will continue to maximize the existing business globally while aiming to further contribute to medical transplantation in the mid- to long-term by accelerating development of compounds in the development pipelines, further strengthening its research and technology base, and setting about the research of pharmaceuticals for regenerative medicine.
Oncology	Aiming to replicate the achievements of urology and transplants and make oncology the third global category leader (GCL), Astellas will quickly establish the oncology business base by actively using OSI's oncology business platform and further reinforcing the development pipelines through applying new targets and the latest technologies.

Astellas will further strengthen its own sales network which covers emerging markets as well as promote balanced global development in Japan, the Americas, Europe and Asia.

Japan	Astellas will aim to gain the largest share of the domestic market during the period of the Mid-Term Management Plan by expanding sales of growing products such as Vesicare and mirabegron, and continuing to launch new products.
Americas	Astellas will aim for further reinforcement and expansion of the business platform by increasing sales of growing products and new products and expanding the business in Latin America.
Europe	Astellas will further strengthen its position as the No. 1 Japanese pharmaceutical company by increasing sales of growing products and further expanding business areas.
Asia	Astellas will aim to realize dramatic growth, especially by expanding business through enhancement of sales organization in the Chinese market, in addition to growth of its mainstay products.

Astellas will take an aggressive drug discovery approach to "precision medicine," i.e. offering highly effective therapeutic options for precisely defined patient populations based on molecular targeting and precision diagnostics.
In addition, we will concentrate our resources on the five focus therapeutic areas aiming to discover innovative new drugs.

Astellas aims to establish a leading position in Precision Medicine by leveraging translational science and biomarker research

Establish a GCL model with Disease Knowledge and Precision Medicine approaches

Efficiency strategy

To improve cost efficiency, Astellas will streamline resource allocation through executing the therapeutic area strategies, better and more sharply manage expenditure, and review all business processes to achieve cost savings.

• Presentation Material for Mid-Term Management Plan (pdf 1.3MB)

---

• Top Message
• • Message from CEO
  • Business Philosophy / Business Plan
  • VISION2015
  • Mid-Term Management Plan
  • CSR-Based Management
• Financial Information
• Stock & Bond Information
• IR Calendar
• IR Library
• Analyst Coverage
• Cautionary Statement